AUTHORS
Gang An, MD, Chanjuan Shen2, Hongyu Zhang, PhD3, Jiao Chen4, Jun Wang5, Huili Cai6, Hang Xiang7, Xuezhong Gu8, Guowei Li9, Bing Chen10, Yanjie He I11, Chunyan Sun, MD12, Wei Wang13, Hong-Hu Zhu, PhD14, Qike Zhang, MD15, Baolai Hua16, Wei Wang17, Lu-Gui Qiu, PhD18
AFFILIATIONS
1 Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2 Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
3 Peking University Shenzhen Hospital, Shenzhen, China
4 Chengdu Second People’s Hospital, Chengdu, China
5 Changde Hospital, Xiangya School of Medicine, Central South University (First People's Hospital of Changde City), Changde, China
6 The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China
7 The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China
8 The First People's Hospital of Yunnan Province, Kunming, China
9 Huizhou Municipal Central Hospital, Huizhou, China
10 Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
11 Zhujiang Hospital, Southern Medical University, Guangzhou, China
12 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13 The Second Affiliated Hospital of Harbin Medical University, Harbin, China
14 Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
15 Gansu Provincial Hospital, Lanzhou, China
16 Beijing Shijitan Hospital, Capital Medical University, Beijing, China
17 Chongqing Genrix Biopharmaceutical Co., Ltd, Chongqing, China
18 Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Multiple myeloma (MM) remains an incurable haematological malignancy characterized by clonal proliferation of plasma cells. Although survival outcomes have significantly improved over the past two decades, yet only 10%–15% of patients could achieve survival comparable to the general population, and the majority of patients inevitably experience disease relapse or refractory to current therapies. Disease heterogeneity intensifies with each subsequent line of treatment, accompanied by progressively shorter duration of responses. For patients who have progressed after frontline treatment including lenalidomide and a proteasome inhibitor (PI), therapeutic options become limited, and triplet regimens such as daratumumab plus pomalidomide and dexamethasone (DPd) serve as the standard of care. However, despite these advances, outcomes remain suboptimal, and there is a continued need for more effective and tolerable options, such as innovative immunotherapeutic approaches.
Velinotamig (GR1803) is a novel, bispecific monoclonal antibody targeting B-cell maturation antigen (BCMA) and CD3, designed to redirect T cells to induce targeted cytotoxicity against BCMA-expressing MM cells. In the phase II (NCT06566547) study, velinotamig monotherapy in heavily treated RRMM patients who had received at least 3 prior lines of therapy, demonstrated robust and durable response with a controllable safety profile. The compelling outcomes provide strong justification for further investigation of velinotamig in earlier treatment settings for RRMM.
Here we report the design of the GR1803-004 trial, a multicenter, open-label, randomized, phase 3 study conducted to compare the efficacy and safety of velinotamig versus DPd in patients with RRMM who have received 1 to 3 prior lines of therapy, including both lenalidomide and a PI.
Study Design and Methods
Eligible patients who have received 1 to 3 prior lines of anti-myeloma therapy including a PI and lenalidomide will be aged ≥18 years, have measurable disease, and an Eastern Cooperative Oncology Group performance status score of 0-2. Patients who received any prior BCMA-directed treatment will be excluded. A total of 358 patients will be randomized 1:1 to receive either velinotamig or DPd in 28-day cycles. The study will continue until progressive disease, death, intolerable toxicity, loss to follow-up, withdrawal of consent, or end of study, whichever occurs first.
The primary endpoint is PFS. The secondary endpoints include OS, PFS2, ORR, complete response rate, DOR, duration of CR or better, time to response, minimal residual disease negative rate, patient-reported outcomes of EQ-5D-5L, and adverse events (AEs).
Response will be assessed using the 2016 International Myeloma Working Group criteria. AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which will be graded per the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.
Results from this pivotal trial may provide critical evidence on the efficacy and safety of velinotamig injection compared to DPd in patients with RRMM in this earlier-line setting (NCT07452198).
DISCLOSURES
Gang An, MD: No relevant conflicts of interest to declare.